212 related articles for article (PubMed ID: 34436898)
21. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
Bork K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
[TBL] [Abstract][Full Text] [Related]
22. Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.
Srinivasan C; Ritchie B; Adatia A
Front Immunol; 2024; 15():1339421. PubMed ID: 38318176
[TBL] [Abstract][Full Text] [Related]
23. An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy.
Lumry WR; Bernstein JA; Li HH; Levy DS; Jones DH; Padilla BE; Li-Mcleod J; Tachdjian R
Allergy Asthma Proc; 2024 Jan; 45(1):44-49. PubMed ID: 38151740
[No Abstract] [Full Text] [Related]
24. An evidence based therapeutic approach to hereditary and acquired angioedema.
Bork K
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
[TBL] [Abstract][Full Text] [Related]
25. Lanadelumab for the prevention of attacks in hereditary angioedema.
Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
[No Abstract] [Full Text] [Related]
26. Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability.
Diaz-Menindez M; Morgenstern-Kaplan D; Cuervo-Pardo L; Alvarez-Arango S; Gonzalez-Estrada A
Ther Clin Risk Manag; 2023; 19():313-317. PubMed ID: 37021074
[TBL] [Abstract][Full Text] [Related]
27. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
Schneider L; Lumry W; Vegh A; Williams AH; Schmalbach T
J Allergy Clin Immunol; 2007 Aug; 120(2):416-22. PubMed ID: 17559913
[TBL] [Abstract][Full Text] [Related]
28. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
Riedl M
Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in the management of hereditary angioedema.
Hemperly SE; Agarwal NS; Xu YY; Zhi YX; Craig TJ
J Am Osteopath Assoc; 2013 Jul; 113(7):546-55. PubMed ID: 23843378
[TBL] [Abstract][Full Text] [Related]
30. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability.
Bernstein JA; Qazi M
Expert Rev Clin Immunol; 2010 Jan; 6(1):29-39. PubMed ID: 20383888
[TBL] [Abstract][Full Text] [Related]
31. Ecallantide for treatment of acute attacks of hereditary angioedema.
Martello JL; Woytowish MR; Chambers H
Am J Health Syst Pharm; 2012 Apr; 69(8):651-7. PubMed ID: 22472866
[TBL] [Abstract][Full Text] [Related]
32. Hereditary angioedema in childhood: an approach to management.
Ebo DG; Verweij MM; De Knop KJ; Hagendorens MM; Bridts CH; De Clerck LS; Stevens WJ
Paediatr Drugs; 2010 Aug; 12(4):257-68. PubMed ID: 20593909
[TBL] [Abstract][Full Text] [Related]
33. Investigational drugs in phase I and phase II clinical trials for hereditary angioedema.
Farkas H; Debreczeni ML; Kőhalmi KV
Expert Opin Investig Drugs; 2018 Jan; 27(1):87-103. PubMed ID: 29226721
[TBL] [Abstract][Full Text] [Related]
34. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery.
Lehmann A
Expert Opin Biol Ther; 2008 Aug; 8(8):1187-99. PubMed ID: 18613770
[TBL] [Abstract][Full Text] [Related]
35. Use of ecallantide in pediatric hereditary angioedema.
MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
[TBL] [Abstract][Full Text] [Related]
36. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
Hwang G; Johri A; Ng S; Craig T
Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
[TBL] [Abstract][Full Text] [Related]
37. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Allergy Asthma Proc; 2012; 33(2):178-85. PubMed ID: 22525395
[TBL] [Abstract][Full Text] [Related]
38. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.
Jacobs J; Neeno T
Postgrad Med; 2021 Aug; 133(6):639-650. PubMed ID: 33993830
[TBL] [Abstract][Full Text] [Related]
39. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.
Stolz LE; Sheffer AL
Expert Rev Clin Immunol; 2012 Jan; 8(1):25-32. PubMed ID: 22149337
[TBL] [Abstract][Full Text] [Related]
40. Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat.
Riedl MA; Soteres D; Sublett JW; Desai B; Tomita D; Collis P; Bernstein JA;
Ann Allergy Asthma Immunol; 2024 Apr; 132(4):505-511.e1. PubMed ID: 38006972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
